Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy
Dual blockade of PD-1/PD-L1 and IL-33/ST2 signalling pathways represents a novel and promising strategy to enhance the efficacy of immunotherapy in breast cancer. This approach has the potential to revert the immunosuppressive TME, leading to more durable and robust anti-tumour responses. Further research is warranted to validate this hypothesis and translate it into effective clinical trials.
Authors
- Milan Jovanović (ORCID: https://orcid.org/0000-0003-0547-2974)
- Marina Jovanovic (ORCID: https://orcid.org/0000-0002-4421-3062)
- Miodrag Jocić (ORCID: https://orcid.org/0000-0002-1704-4208)
- Milena Jurišević (ORCID: https://orcid.org/0000-0002-0553-1156)
- Ivan Jovanović (ORCID: https://orcid.org/0000-0002-1169-2378)
- Nevena Gajović (ORCID: https://orcid.org/0000-0003-0535-2964)
Institutions
- Military Medical Academy (RS)
- University of Kragujevac (RS)
- University of East Sarajevo (BA)
- Military Medical Academy (EG)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1080/07853890.2025.2593198
- Citations
- 1
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.80